NuVasive

Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results

Retrieved on: 
Wednesday, January 10, 2024
Seed, Patient, Health, CFO, Spine, Enabling, Globus Medical, Globus, NuVasive

AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.

Key Points: 
  • AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2023.
  • The company anticipates fourth quarter 2023 sales of approximately $615.5 million, an increase of 124.2 percent over the fourth quarter 2022 on an as-reported basis.
  • “Excluding the impacts of the September 1, 2023 merger with NuVasive, Inc., legacy Globus fourth quarter revenue was approximately $302.9 million, an increase of 10.4 percent over the prior year fourth quarter.
  • The company expects to announce its fourth quarter and full year 2023 financial results on February 20, 2024, after the market close.

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Retrieved on: 
Wednesday, January 3, 2024
NSPR, NuVasive, TEL, Stroke, Integra, IDE, Globus Medical, Integra LifeSciences, Orthopedic surgery, Growth, Rutgers University, Patient, Compensated emancipation, Stenosis, Employment, Syracuse University, NSO, EPS, Senior

TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.

Key Points: 
  • TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America.
  • Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team.
  • Before that, he served as Vice President of Global Commercial Strategy at Smith+Nephew, and, prior to that, in various roles of increasing responsibility at Integra LifeSciences, culminating with Senior Vice President and General Manager - Extremity Orthopedics.
  • In connection with the appointment of Mr. Ligotti as Executive Vice President and General Manager of North America, InspireMD has granted Mr. Ligotti 138,460 shares of restricted stock and stock options to purchase 46,150 shares of InspireMD’s common stock.

Orthofix Names Massimo Calafiore as President and Chief Executive Officer

Retrieved on: 
Tuesday, November 28, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Managed Care, Sale, EBITDA, Acquisition, NYSE, Heidrick & Struggles, Interim, ENOV, Mechanical engineering, NuVasive, Spine, Surgeon, Orthopedic surgery, Elective surgery, Ankle, Patient, Multimedia, Mentorship, Sustainability Accounting Standards Board, Ellipse, MBA, University, Trauma, Growth, Knowledge, University of Catania, Management, Nursing, New York University

(NASDAQ:OFIX), a leading global spine and orthopedics company, announced today that Massimo Calafiore has been named incoming President and Chief Executive Officer.

Key Points: 
  • (NASDAQ:OFIX), a leading global spine and orthopedics company, announced today that Massimo Calafiore has been named incoming President and Chief Executive Officer.
  • Mr. Calafiore is currently Chief Executive Officer of LimaCorporate S.p.A., a global orthopedics company, and his appointment to Orthofix is expected to be effective in early 2024, following the completion of LimaCorporate’s previously announced acquisition by Enovis Corporation (NYSE: ENOV).
  • At that time, Mr. Calafiore is also expected to join Orthofix’s Board of Directors.
  • At the beginning of his tenure at NuVasive, Mr. Calafiore served as President of NuVasive Specialized Orthopedics (formerly Ellipse Technologies).

VISIE™ Inc. Adds Powerhouse Medtech Veterans to Board & Leadership Team to Support Next Phase of Growth

Retrieved on: 
Tuesday, November 14, 2023
Software, Research, Radiology, Hardware, Medical Devices, Technology, Health Technology, Science, Surgery, Biotechnology, Other Technology, Health, Materialise NV, Interface (computing), Acquisition, Johnson & Johnson, Springboard, Tufts University, Executive Committee, Lincoln University, University, Robotics, Mechanical engineering, Peter Head (civil engineer), NuVasive, Entrepreneurship, Spine, History, Multimedia, Patient, Computer science, Biomedicine, Neuro, Medtech, MBA, Growth, 3D, Physical therapy, Biomedical engineering, Mechanical, 3D printing, Management, Austin, Texas, Engineering

Adds Medtech Veterans to Board and Leadership Team: Addie Harris (left), Ashley Libby Diaz, PT, MBA (middle), and Michael Landry (right) (Photo: Business Wire)

Key Points: 
  • Adds Medtech Veterans to Board and Leadership Team: Addie Harris (left), Ashley Libby Diaz, PT, MBA (middle), and Michael Landry (right) (Photo: Business Wire)
    Addie Harris brings a robust history of entrepreneurship in medtech, medical devices, and robotics to the VISIE board.
  • Ashley Libby Diaz, VISIE’s new Head of Marketing, brings 25-plus years of healthcare, medtech, and medical device experience to the organization.
  • “I am thrilled to add such talented and experienced individuals to our board and leadership team.
  • The company has entered a phase of growth the likes of which I have not seen before.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

John Booth to Retire as CEO of Spineology Inc.

Retrieved on: 
Thursday, November 9, 2023
Medical Devices, Health, Hospitals, Surgery, General Health, Biotechnology, ATEC, BBA, Spine, Duke University, Fuqua School, George Washington University, Snider, MBA, NuVasive, Triple accreditation, Growth, Inc., Business, Information system, Biopharmaceutical, Management, Vertebral column, Marketing

Spineology Inc. (“Spineology” or the “Company”), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023.

Key Points: 
  • Spineology Inc. (“Spineology” or the “Company”), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023.
  • Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition.
  • Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director.
  • Snider joins Spineology with nearly twenty years of progressive leadership experience in the medical device industry.

Globus Medical Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
DSM-IV codes, NYSE, Globus Medical, EBITDA, Telephone, GAAP, Acquisition, NuVasive, EPS, ID, Surgeon, Webcast, Culture, Patient, Pharmaceutical industry, Video game

AUDUBON, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • AUDUBON, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2023.
  • The merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date.
  • Non-GAAP adjusted EBITDA was $112.9 million, or 29.4% of net sales
    Stand-alone Globus Medical net sales were $281.2 million, an increase of 10.7%
    “The third quarter of 2023 was a defining moment for Globus Medical, as we completed our planned merger with NuVasive to create the most innovative company in the spine industry.
  • Globus Medical will hold a teleconference to discuss its third quarter 2023 results with the investment community at 4:30 p.m. Eastern Time today.

Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum

Retrieved on: 
Tuesday, October 10, 2023
Diagnosis, Neoplasm, Partnership, NYSE, Health care, MIS, Economics, Standard of care, Comparison, Globus Medical, Safety, Health, Rush University Medical Center, Spine, Patient, E pluribus unum, Society, Education, Deformity, Trauma, Surgeon, NuVasive, Risk management, Ayaka Miyauchi, Research, Dentistry, Bookbinding, Hospital, Silviculture

AUDUBON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, celebrated twenty years of the NuVasive XLIF procedure at the Society for Minimally Invasive Spine Surgery (SMISS) ’23 Annual Forum.

Key Points: 
  • AUDUBON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, celebrated twenty years of the NuVasive XLIF procedure at the Society for Minimally Invasive Spine Surgery (SMISS) ’23 Annual Forum.
  • “Very few medical technology innovations have transformed an industry like the NuVasive XLIF procedure.
  • Hosted by NuVasive, the evening event featured more than 20 surgeon speakers discussing the past, present and future impact of the procedure.
  • Economics of less invasive spinal surgery: an analysis of hospital cost differences between open and minimally invasive instrumented spinal fusion procedures during the perioperative period.

LivaNova Board Appoints J. Christopher Barry as New Director

Retrieved on: 
Friday, October 6, 2023
Medical Devices, Surgery, Hospitals, Clinical Trials, Health Technology, Cardiology, Other Health, Biotechnology, General Health, Health, Surgical Innovation, Medtronic, Senior, Retirement, Texas Tech University, Audit, LivaNova, Interim, LIVN, Growth, Marketing, PLC, Environmental science, NuVasive, Covidien, Patient, Pension fund, Management

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.

Key Points: 
  • LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today.
  • Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December 31, 2023.
  • “The LivaNova Board of Directors is pleased to welcome Chris Barry,” said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova.
  • With these changes, the LivaNova Board will be comprised of 10 Directors until Saia’s retirement at the end of the year.